Skip to main content

Spinal Muscular Atrophy: Drugs

Question for Department of Health

UIN 58640, tabled on 20 December 2016

To ask the Secretary of State for Health, what discussions his Department has had with representatives from (a) NHS England, (b) Biogen pharmaceutical company and (c) patient groups on the Expanded Access programme for nusinersen for the treatment of infants with spinal muscular atrophy type 1.

Answered on

9 January 2017

We have had no such discussions.

Biogen Ltd submitted a marketing authorisation application for nusinersen to the European Medicines Agency in October 2016. The application has been approved for accelerated assessment by the Committee for Medicinal Products for Human Use. The licensing procedure is likely to take some months to complete. If approved, the product will be authorised for marketing in all European Union member states.

Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.